{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:09:10Z","timestamp":1788030550456,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03029-6","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T13:02:08Z","timestamp":1717160528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China"],"prefix":"10.1007","volume":"316","author":[{"given":"Sisi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"issue":"3 Suppl 1","key":"3029_CR1","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","volume":"78","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA, Dupilumab (2018) A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 78(3 Suppl 1):S28\u2013s36","journal-title":"J Am Acad Dermatol"},{"issue":"10086","key":"3029_CR2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287\u20132303","journal-title":"Lancet"},{"issue":"8","key":"3029_CR3","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/jdv.15609","volume":"33","author":"CM Olesen","year":"2019","unstructured":"Olesen CM, Holm JG, N\u00f8rreslet LB, Serup JV, Thomsen SF, Agner T (2019) Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 33(8):1562\u20131568","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"3029_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","volume":"158","author":"LS Spekhorst","year":"2022","unstructured":"Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek J, Kamsteeg M, Boesjes CM et al (2022) Dupilumab Drug Survival and Associated Predictors in patients with moderate to severe atopic dermatitis: long-term results from the Daily Practice BioDay Registry. JAMA Dermatol 158(9):1048\u20131056","journal-title":"JAMA Dermatol"},{"issue":"6","key":"3029_CR5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/bjd.21794","volume":"187","author":"D St\u00f6lzl","year":"2022","unstructured":"St\u00f6lzl D, Sander N, Heratizadeh A, Haufe E, Harder I, Abraham S et al (2022) Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol 187(6):1022\u20131024","journal-title":"Br J Dermatol"},{"issue":"6","key":"3029_CR6","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/jdv.18889","volume":"37","author":"E Pezzolo","year":"2023","unstructured":"Pezzolo E, Rossi M, Caroppo F, Bianchelli T, Belloni Fortina A, Giacchetti A et al (2023) Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: a real-world prospective cohort study. J Eur Acad Dermatol Venereol 37(6):e757\u2013e759","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3029_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V et al (2021) Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol 126(1):40\u201345","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3029_CR8","doi-asserted-by":"publisher","first-page":"2230685","DOI":"10.1080\/09546634.2023.2230685","volume":"34","author":"N Gori","year":"2023","unstructured":"Gori N, Sernicola A, Tolino E, Mariano M, Galluzzo M, Moretta G et al (2023) Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study. J Dermatolog Treat 34(1):2230685","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"3029_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13555-021-00505-z","volume":"11","author":"M Napolitano","year":"2021","unstructured":"Napolitano M, Ferrillo M, Patruno C, Scalvenzi M, D\u2019Andrea M, Fabbrocini G (2021) Efficacy and safety of Dupilumab in Clinical Practice: one year of experience on 165 adult patients from a Tertiary Referral Centre. Dermatol Ther (Heidelb) 11(2):355\u2013361","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"3029_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jaad.2019.12.034","volume":"82","author":"H Khosravi","year":"2020","unstructured":"Khosravi H, Zhang S, Anderson AM, Ferris LK, Choudhary S, Patton T (2020) Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. J Am Acad Dermatol 82(4):1023\u20131024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3029_CR11","doi-asserted-by":"publisher","first-page":"e13979","DOI":"10.1111\/dth.13979","volume":"33","author":"G Dal Bello","year":"2020","unstructured":"Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P (2020) Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatol Ther 33(6):e13979","journal-title":"Dermatol Ther"},{"issue":"3","key":"3029_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.19577","volume":"184","author":"E Nettis","year":"2021","unstructured":"Nettis E, Fabbrocini G, Ortoncelli M, Pellacani G, Argenziano G, Di Leo E et al (2021) Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients. Br J Dermatol 184(3):561\u2013563","journal-title":"Br J Dermatol"},{"key":"3029_CR13","doi-asserted-by":"crossref","unstructured":"Ferrucci S, Casazza G, Angileri L, Tavecchio S, Germiniasi F, Berti E et al (2020) Clinical response and quality of life in patients with severe atopic dermatitis treated with Dupilumab: a single-Center Real-Life experience. J Clin Med. ;9(3)","DOI":"10.3390\/jcm9030791"},{"issue":"4","key":"3029_CR14","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D et al (2021) Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol 147(4):1174\u20131190e1171","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3029_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S et al (2020) Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy 75(5):1188\u20131204","journal-title":"Allergy"},{"issue":"5","key":"3029_CR16","doi-asserted-by":"publisher","first-page":"e15385","DOI":"10.1111\/dth.15385","volume":"35","author":"Y Li","year":"2022","unstructured":"Li Y, Lu J, Chen R, Wang Y, Ding Y, Xu S et al (2022) The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: a single-center retrospective study. Dermatol Ther 35(5):e15385","journal-title":"Dermatol Ther"},{"issue":"1","key":"3029_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP (2021) Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol 84(1):139\u2013147","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3029_CR18","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/all.14338","volume":"75","author":"E Nettis","year":"2020","unstructured":"Nettis E, Patella V, Lombardo C, Detoraki A, Macchia L, Di Leo E et al (2020) Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. Allergy 75(10):2653\u20132661","journal-title":"Allergy"},{"issue":"5","key":"3029_CR19","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","volume":"6","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegr\u00e4ber M, de Bruin-Weller M (2018) Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6(5):1778\u20131780e1771","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"3029_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.18176\/jiaci.0641","volume":"32","author":"E Nettis","year":"2022","unstructured":"Nettis E, Ferrucci SM, Ortoncelli M, Pellacani G, Foti C, Di Leo E et al (2022) Use of Dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: a Multicenter, Retrospective Study. J Investig Allergol Clin Immunol 32(2):124\u2013132","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"3029_CR21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","volume":"86","author":"MJ Murphy","year":"2022","unstructured":"Murphy MJ, Cohen JM, Vesely MD, Damsky W (2022) Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol 86(5):1080\u20131091","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3029_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jdcr.2017.11.020","volume":"4","author":"K Mitchell","year":"2018","unstructured":"Mitchell K, Levitt J (2018) Alopecia Areata after dupilumab for atopic dermatitis. JAAD Case Rep 4(2):143\u2013144","journal-title":"JAAD Case Rep"},{"issue":"8","key":"3029_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jdcr.2019.03.019","volume":"5","author":"J Chung","year":"2019","unstructured":"Chung J, Slaught CL, Simpson EL (2019) Alopecia Areata in 2 patients treated with dupilumab: new onset and worsening. JAAD Case Rep 5(8):643\u2013645","journal-title":"JAAD Case Rep"},{"issue":"1","key":"3029_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdcr.2018.10.010","volume":"5","author":"K Flanagan","year":"2019","unstructured":"Flanagan K, Sperling L, Lin J (2019) Drug-induced alopecia after dupilumab therapy. JAAD Case Rep 5(1):54\u201356","journal-title":"JAAD Case Rep"},{"issue":"2","key":"3029_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.18176\/jiaci.0682","volume":"32","author":"FJ Mu\u00f1oz-Bellido","year":"2022","unstructured":"Mu\u00f1oz-Bellido FJ, Moreno E, D\u00e1vila I, Dupilumab (2022) A review of Present indications and off-label uses. J Investig Allergol Clin Immunol 32(2):97\u2013115","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03029-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:40:43Z","timestamp":1719402043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03029-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3029"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03029-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reviewed and approved by the Ethical Committee of the First Affiliated Hospital of Army Medical University of the People\u2019s Liberation Army; approval: #(B) KY2023115.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The ethic committee approved waiver of informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"304"}}